Table 3

Comparison of the clinical characteristics between Group 1A (cases in which transparency was maintained after recovery from rejection, n = 25) and Group 1B (cases in which the decompensation occurring after transparency recovered, n = 12)
Group 1A Group 1B OR P-Value
mean ± SD mean ± SD (95% CI)
n (%) n (%)
Age (years) 58.4 ± 17.4 61.5 ± 10.8 0.99 (0.94–1.03) 0.57
Sex
 Male 17 (68.0) 6 (50.0) 2.13 (0.52–8.70) 0.29
 Female 8 (32.0) 6 (50.0)
Diagnosis before previous PKP
 Bullous keratopathy 8 (32.0) 5 (41.7) 0.66 (0.16–2.73) 0.57
 Regraft 2 (8.0) 6 (50.0) 0.09 (0.01–0.54) 0.0091
 Corneal scarring 8 (32.0) 1 (8.3) 5.18 (0.57–47.32) 0.14
 Corneal dystrophy 3 (12.0) 0 (0.0) 1.00
 Keratoconus 3 (12.0) 0 (0.0) 1.00
 Corneal ulcer 1 (4.0) 0 (0.0) 1.00
Type of surgery
 PKP 17 ((68.0) 10 (83.3) 0.43 (0.08–2.41) 0.33
 PKP + ECCE + IOL 7 (28.0) 2 (16.7) 1.94 (0.34–11.20) 0.46
 PKP + IOL suture 1 (4.0) 0 (0.0) 1.00
history of glaucoma 5 (20.0) 3 (25.0) 0.75 (0.15-3.84) 0.73
Previous episodes of rejection 1 (4.0) 4 (33.3) 0.13 (0.01–1.36) 0.09
ECD before rejection 1523 ± 666 2010 ± 876 0.999 (0.998–1.001) 0.19
Interval between PKP and rejection (months) 41.3 ± 44.2 16.8 ± 23.3 1.03 (0.99–1.06) 0.12
Interval between rejection and treatment with systemic steroids (days) 6.5 ± 5.5 5.8 ± 6.1 1.02 (0.89–1.15) 0.80
Systemic steroid
 Dexamethasone phosphate 20 (80.0) 9 (75.0) 1.33 (0.26–6.83) 0.73
 Methylprednisolone 5 (20.0) 3 (25.0) 0.75 (0.15–3.84) 0.73
Interval between treatment and recovery of transparency (days) 72.5 ± 70.4 93.0 ± 208.0 0.999 (0.994–1.004) 0.65

ECCE, extracapsular cataract extraction; ECD, endothelial cell density; IOL, intraocular lens; PKP, penetrating keratoplasty; SD, standard deviation.

Yamazoe et al.

Yamazoe et al. BMC Ophthalmology 2013 13:5   doi:10.1186/1471-2415-13-5

Open Data